ovid stock quote Company Overview and Financial Insights

Author

Reads 719

Free stock photo of analysis, analytics, bar graph
Credit: pexels.com, Free stock photo of analysis, analytics, bar graph

Ovid Technologies is a leading provider of clinical trial management and regulatory compliance solutions for the life sciences industry. Ovid Technologies was founded in 1995 and is headquartered in New York City.

The company's flagship product, Ovid, is a comprehensive clinical trial management system that streamlines the clinical trial process from start to finish. This includes electronic data capture, clinical trial management, and regulatory compliance.

Ovid Technologies has a strong track record of innovation, with a focus on delivering cutting-edge technology and exceptional customer support.

Performance

The performance of Ovid Therapeutics stock has been quite volatile in recent years. The 52-week high is a staggering US$4.10, while the 52-week low is a lowly US$0.68.

The stock's beta is a relatively low 0.34, indicating that its price movements tend to be less volatile compared to the overall market. However, this hasn't stopped the stock from experiencing significant price swings, with a 1-month change of -24.97% and a 3-month change of -36.70%.

Credit: youtube.com, The Stock OVID

In the past year, the stock has plummeted by an astonishing -81.48%, while its 3-year change is a -74.46% decline. The 5-year change is an even more dramatic -80.06%. If you had invested in Ovid Therapeutics at its IPO, you would have seen a -94.06% decline in the stock's value.

Here's a summary of the stock's performance over different time periods:

The stock's previous close was US$0.732, with a day range of US$0.7 to US$0.758. The year range is even more dramatic, with a low of US$0 and a high of US$4. The stock's market capitalization is a relatively modest US$51,965,000, and it's listed on the NASDAQ exchange.

In terms of financial performance, Ovid Therapeutics has reported a diluted EPS (TTM) of -0.46. The company's revenue growth year-over-year (YOY) is a respectable 58.7%, while its earnings growth YOY is a flat 0%. The profit margin is also a zero, indicating that the company is not generating any profits.

Analysts are predicting a significant increase in the stock's price, with an average target of US$4.04. This represents a potential increase of 455.02% from the current stock price of US$0.73. However, it's worth noting that the analysts' predictions are quite varied, with a low estimate of US$1.20 and a high estimate of US$8.00.

A different take: S B I Card Share Price

Company Information

Credit: youtube.com, 🔴 Ovid Therapeutics Inc OVID Stock Information 🔴

Ovid Technologies is a global provider of clinical trial management and regulatory information management solutions.

Ovid Technologies is a subsidiary of Wolters Kluwer, a multinational information services and publishing company.

Wolters Kluwer is headquartered in Alphen aan den Rijn, Netherlands, and has operations in over 180 countries.

Ovid Technologies has a presence in major markets globally, including North America, Europe, and Asia Pacific.

Danielle Hamill

Senior Writer

Danielle Hamill is a seasoned writer with a keen eye for detail and a passion for storytelling. With a background in finance, she brings a unique perspective to her writing, tackling complex topics with clarity and precision. Her work has been featured in various publications, covering a range of topics including cryptocurrency regulatory alerts.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.